Viemed Healthcare (VMD) Financials

$9.49 0.00 (0.00%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$9.49 +0.00 (+0.05%)

As of 04:05 AM Eastern

Annual Income Statements for Viemed Healthcare

This table shows Viemed Healthcare's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	6.22	10	11
Consolidated Net Income / (Loss)	6.22	10	11
Net Income / (Loss) Continuing Operations	6.22	10	11
Total Pre-Tax Income	8.99	14	16
Total Operating Income	8.25	14	18
Total Gross Profit	85	113	133
Total Revenue	139	183	224
Operating Revenue	139	183	224
Total Cost of Revenue	54	70	91
Operating Cost of Revenue	54	70	91
Total Operating Expenses	77	99	117
Selling, General & Admin Expense	68	88	106
Research & Development Expense	2.70	2.78	3.07
Depreciation Expense	1.01	1.39	1.48
Other Operating Expenses / (Income)	5.20	5.85	6.29
Total Other Income / (Expense), net	1.73	0.16	0.00
Interest & Investment Income	0.74	0.06	-1.73
Other Income / (Expense), net	0.99	0.10	1.73
Income Tax Expense	2.77	4.15	4.76
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	0.00	0.14
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-	-	0.00
Basic Earnings per Share	$0.16	$0.27	$0.29
Weighted Average Basic Shares Outstanding	38.66M	38.35M	38.75M
Diluted Earnings per Share	$0.16	$0.25	$0.28
Weighted Average Diluted Shares Outstanding	39.81M	40.38M	40.81M
Weighted Average Basic & Diluted Shares Outstanding	38.17M	38.76M	39.52M

This table shows Viemed Healthcare's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	1.17	2.33	1.52	2.33	2.92	3.48	1.60	1.47	3.88	4.32
Consolidated Net Income / (Loss)	1.06	2.44	1.52	2.33	2.92	3.48	1.60	1.48	3.91	4.42
Net Income / (Loss) Continuing Operations	1.06	2.44	1.52	2.33	2.92	3.48	1.60	1.48	3.91	4.42
Total Pre-Tax Income	1.51	3.58	2.02	3.06	4.24	5.08	2.12	2.25	5.50	6.31
Total Operating Income	1.47	3.53	1.93	2.90	4.21	5.29	2.20	3.62	5.63	6.45
Total Gross Profit	22	23	24	26	31	32	30	33	34	36
Total Revenue	36	38	40	43	49	51	51	55	58	61
Operating Revenue	36	38	40	43	49	51	51	55	58	61
Total Cost of Revenue	14	15	16	17	19	19	21	22	24	25
Operating Cost of Revenue	14	15	16	17	19	19	21	22	24	25
Total Operating Expenses	20	20	22	23	26	27	28	29	29	32
Selling, General & Admin Expense	18	17	20	21	24	24	25	27	27	28
Research & Development Expense	0.67	0.72	0.78	0.76	0.59	0.65	0.75	0.76	0.76	0.80
Depreciation Expense	0.29	0.24	0.24	0.30	0.42	0.43	0.42	0.38	0.35	0.34
Other Operating Expenses / (Income)	1.31	1.98	1.39	1.47	1.45	1.53	1.43	1.62	1.71	1.52
Total Other Income / (Expense), net	0.10	0.98	0.17	0.16	0.07	-0.24	-0.06	-1.93	0.15	1.85
Interest & Investment Income	0.04	0.05	0.08	0.16	0.03	-0.21	-0.08	-1.37	-0.13	-0.15
Other Income / (Expense), net	0.06	-	0.08	0.00	0.04	-0.03	0.03	-0.56	0.28	1.99
Income Tax Expense	0.46	1.15	0.50	0.73	1.32	1.60	0.52	0.77	1.59	1.88
Basic Earnings per Share	$0.03	$0.07	$0.04	$0.06	$0.08	$0.09	$0.04	$0.04	$0.10	$0.11
Weighted Average Basic Shares Outstanding	38.23M	38.66M	38.16M	38.32M	38.44M	38.35M	38.72M	38.82M	38.87M	38.75M
Diluted Earnings per Share	$0.03	$0.07	$0.04	$0.06	$0.07	$0.08	$0.04	$0.04	$0.10	$0.10
Weighted Average Diluted Shares Outstanding	39.58M	39.81M	40.02M	40.68M	40.42M	40.38M	40.58M	40.55M	40.78M	40.81M
Weighted Average Basic & Diluted Shares Outstanding	38.02M	38.17M	38.28M	38.40M	38.49M	38.76M	38.82M	38.83M	38.94M	39.52M

This table details how cash moves in and out of Viemed Healthcare's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-11	-4.08	4.70
Net Cash From Operating Activities	28	45	39
Net Cash From Continuing Operating Activities	28	45	39
Net Income / (Loss) Continuing Operations	6.22	10	11
Consolidated Net Income / (Loss)	6.22	10	11
Depreciation Expense	16	22	25
Amortization Expense	0.00	0.00	0.19
Non-Cash Adjustments To Reconcile Net Income	4.27	6.77	5.61
Changes in Operating Assets and Liabilities, net	1.62	6.34	-3.49
Net Cash From Investing Activities	-24	-52	-31
Net Cash From Continuing Investing Activities	-24	-52	-31
Purchase of Property, Plant & Equipment	-23	-26	-39
Acquisitions	0.00	-29	-3.00
Purchase of Investments	-2.00	0.00	0.00
Sale of Property, Plant & Equipment	1.06	2.59	10
Sale and/or Maturity of Investments	0.00	0.00	0.75
Net Cash From Financing Activities	-15	2.83	-3.69
Net Cash From Continuing Financing Activities	-15	2.83	-3.69
Repayment of Debt	-5.80	-11	-6.60
Repurchase of Common Equity	-9.57	0.00	0.00
Payment of Dividends	0.00	0.00	-0.04
Issuance of Debt	0.00	13	3.00
Other Financing Activities, net	0.10	0.55	-0.05
Cash Interest Paid	0.23	0.85	0.95
Cash Income Taxes Paid	-0.85	3.57	6.83

This table details how cash moves in and out of Viemed Healthcare's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-0.44	-4.56	6.63	-13	-0.15	2.76	-5.53	1.50	2.54	6.19
Net Cash From Operating Activities	7.97	7.68	10	7.62	14	13	1.18	10	13	15
Net Cash From Continuing Operating Activities	7.97	7.68	10	7.62	14	13	1.18	10	13	15
Net Income / (Loss) Continuing Operations	1.06	2.44	1.52	2.33	2.92	3.48	1.60	1.48	3.91	4.42
Consolidated Net Income / (Loss)	1.06	2.44	1.52	2.33	2.92	3.48	1.60	1.48	3.91	4.42
Depreciation Expense	4.12	4.37	4.76	5.21	5.98	5.92	6.29	6.31	6.41	6.37
Amortization Expense	-	-	-	-	-	-	-	-	0.05	0.05
Non-Cash Adjustments To Reconcile Net Income	1.84	1.56	1.47	1.59	1.85	1.86	1.57	2.25	1.37	0.42
Changes in Operating Assets and Liabilities, net	0.96	-0.69	2.74	-1.51	3.07	2.03	-8.29	0.06	1.01	3.73
Net Cash From Investing Activities	-6.10	-7.38	-3.91	-32	-8.51	-7.49	-5.37	-11	-4.97	-9.20
Net Cash From Continuing Investing Activities	-6.10	-7.38	-3.91	-32	-8.51	-7.49	-5.37	-11	-4.97	-9.20
Purchase of Property, Plant & Equipment	-6.36	-5.57	-4.68	-6.09	-7.40	-7.95	-6.01	-8.93	-11	-13
Sale of Property, Plant & Equipment	0.25	0.19	0.78	1.00	0.35	0.46	0.64	0.77	6.03	2.88
Net Cash From Financing Activities	-2.31	-4.87	0.04	11	-5.45	-3.03	-1.34	2.48	-5.24	0.40
Net Cash From Continuing Financing Activities	-2.31	-4.87	0.04	11	-5.45	-3.03	-1.34	2.48	-5.24	0.40
Repayment of Debt	-0.48	-4.36	0.00	-2.36	-5.42	-2.94	-0.59	-0.62	-5.23	-0.16
Other Financing Activities, net	0.02	0.20	0.04	0.63	-0.03	-0.09	-0.75	0.10	-0.00	0.60
Cash Interest Paid	0.06	0.05	0.04	0.13	0.33	0.35	0.22	0.29	0.23	0.21
Cash Income Taxes Paid	0.02	0.07	-0.04	3.13	0.13	0.35	0.00	3.84	2.58	0.41

This table presents Viemed Healthcare's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Total Assets	117	155	177
Total Current Assets	40	38	53
Cash & Equivalents	17	13	18
Accounts Receivable	15	18	25
Inventories, net	3.57	4.63	4.32
Prepaid Expenses	3.85	2.45	6.11
Plant, Property, & Equipment, net	68	74	76
Total Noncurrent Assets	9.56	43	48
Long-Term Investments	-	1.68	2.79
Noncurrent Note & Lease Receivables	0.00	0.40	0.05
Goodwill	0.00	30	33
Intangible Assets	0.00	0.57	0.85
Noncurrent Deferred & Refundable Income Taxes	3.12	4.56	8.40
Other Noncurrent Operating Assets	6.44	5.98	2.83
Total Liabilities & Shareholders' Equity	117	155	177
Total Liabilities	20	41	44
Total Current Liabilities	19	32	37
Short-Term Debt	0.00	1.07	0.41
Accounts Payable	2.65	4.18	5.32
Accrued Expenses	11	18	20
Current Deferred Revenue	4.62	6.21	6.69
Current Deferred & Payable Income Tax Liabilities	0.00	2.15	3.88
Other Current Liabilities	0.50	0.93	0.86
Total Noncurrent Liabilities	1.09	8.88	6.44
Long-Term Debt	0.00	6.00	3.59
Other Noncurrent Operating Liabilities	1.09	2.87	2.85
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	97	114	133
Total Preferred & Common Equity	97	114	131
Total Common Equity	97	114	131
Common Stock	27	34	42
Retained Earnings	70	79	90
Noncontrolling Interest	-	0.00	1.91

This table presents Viemed Healthcare's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	119	125	149	149	155	164	170
Total Current Assets	43	47	36	36	39	45	48
Cash & Equivalents	21	24	10	10	7.31	8.81	11
Short-Term Investments	2.22	1.99	-	-	-	1.79	1.79
Accounts Receivable	15	16	18	18	24	27	27
Inventories, net	3.18	3.45	4.48	4.67	4.35	4.42	4.31
Prepaid Expenses	3.14	3.39	2.33	3.19	2.48	4.24	4.99
Plant, Property, & Equipment, net	68	68	73	73	74	75	74
Total Noncurrent Assets	6.23	5.44	40	40	43	41	45
Noncurrent Note & Lease Receivables	-	-	0.54	0.53	0.30	0.13	0.07
Goodwill	-	-	30	30	30	33	33
Intangible Assets	-	-	0.69	0.69	0.53	0.91	0.88
Noncurrent Deferred & Refundable Income Taxes	3.93	3.84	3.84	3.91	4.56	4.56	8.07
Other Noncurrent Operating Assets	2.30	1.60	5.46	5.28	7.59	2.89	2.76
Total Liabilities & Shareholders' Equity	119	125	149	149	155	164	170
Total Liabilities	26	25	45	41	39	43	43
Total Current Liabilities	21	23	32	32	30	31	36
Short-Term Debt	0.17	-	3.17	1.83	0.60	0.77	0.81
Accounts Payable	3.74	4.26	6.17	5.98	5.80	6.33	6.01
Accrued Expenses	12	13	16	17	14	17	20
Current Deferred Revenue	4.65	4.70	5.96	6.22	6.09	6.72	6.82
Current Deferred & Payable Income Tax Liabilities	-	1.25	-	0.23	2.68	0.00	2.08
Other Current Liabilities	-	0.40	0.77	0.58	0.90	0.85	0.81
Total Noncurrent Liabilities	4.95	1.17	13	9.03	8.49	11	6.29
Long-Term Debt	4.16	-	12	8.10	5.91	8.72	3.65
Other Noncurrent Operating Liabilities	0.56	1.17	0.92	0.94	2.58	2.57	2.64
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	94	100	105	109	116	121	127
Total Preferred & Common Equity	94	100	105	109	116	119	125
Total Common Equity	94	100	105	109	116	119	125
Common Stock	26	29	31	33	36	38	40
Retained Earnings	68	71	73	76	80	82	85
Noncontrolling Interest	-	-	-	-	-	1.81	1.84

This table displays calculated financial ratios and metrics derived from Viemed Healthcare's official financial filings.

Metric	2022	2023	2024
Period end date	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-
Revenue Growth	18.60%	31.82%	22.54%
EBITDA Growth	8.64%	45.91%	24.52%
EBIT Growth	-20.20%	56.13%	36.07%
NOPAT Growth	-32.43%	78.59%	23.83%
Net Income Growth	-31.82%	64.63%	11.38%
EPS Growth	-27.27%	56.25%	12.00%
Operating Cash Flow Growth	23.36%	62.94%	-13.54%
Free Cash Flow Firm Growth	57.96%	-607.71%	113.16%
Invested Capital Growth	11.06%	32.76%	9.88%
Revenue Q/Q Growth	4.16%	7.79%	4.65%
EBITDA Q/Q Growth	4.68%	10.33%	9.22%
EBIT Q/Q Growth	-1.51%	14.74%	19.34%
NOPAT Q/Q Growth	-19.10%	13.67%	7.77%
Net Income Q/Q Growth	-20.95%	11.29%	9.05%
EPS Q/Q Growth	-15.79%	4.17%	7.69%
Operating Cash Flow Q/Q Growth	-3.38%	14.14%	4.56%
Free Cash Flow Firm Q/Q Growth	-372.31%	34.95%	-32.73%
Invested Capital Q/Q Growth	6.92%	-2.04%	-0.24%
Profitability Metrics	-	-	-
Gross Margin	60.99%	61.63%	59.40%
EBITDA Margin	17.91%	19.83%	20.15%
Operating Margin	5.94%	7.83%	7.98%
EBIT Margin	6.66%	7.88%	8.75%
Profit (Net Income) Margin	4.48%	5.60%	5.09%
Tax Burden Percent	69.21%	71.18%	70.56%
Interest Burden Percent	97.28%	99.74%	82.37%
Effective Tax Rate	30.79%	28.82%	29.44%
Return on Invested Capital (ROIC)	7.50%	10.93%	11.31%
ROIC Less NNEP Spread (ROIC-NNEP)	4.91%	10.57%	21.57%
Return on Net Nonoperating Assets (RNNOA)	-1.01%	-1.22%	-2.08%
Return on Equity (ROE)	6.48%	9.71%	9.23%
Cash Return on Invested Capital (CROIC)	-2.98%	-17.22%	1.89%
Operating Return on Assets (OROA)	7.86%	10.61%	11.83%
Return on Assets (ROA)	5.30%	7.53%	6.87%
Return on Common Equity (ROCE)	6.48%	9.71%	9.16%
Return on Equity Simple (ROE_SIMPLE)	6.41%	8.99%	8.68%
Net Operating Profit after Tax (NOPAT)	5.71	10	13
NOPAT Margin	4.11%	5.57%	5.63%
Net Nonoperating Expense Percent (NNEP)	2.58%	0.36%	-10.27%
Return On Investment Capital (ROIC_SIMPLE)	5.88%	8.43%	9.20%
Cost of Revenue to Revenue	39.01%	38.37%	40.60%
SG&A Expenses to Revenue	49.10%	48.02%	47.36%
R&D to Revenue	1.94%	1.52%	1.37%
Operating Expenses to Revenue	55.76%	53.85%	52.19%
Earnings before Interest and Taxes (EBIT)	9.24	14	20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	25	36	45
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.96	2.65	2.38
Price to Tangible Book Value (P/TBV)	2.96	3.62	3.20
Price to Revenue (P/Rev)	2.07	1.65	1.39
Price to Earnings (P/E)	46.20	29.50	27.72
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	2.16%	3.39%	3.61%
Enterprise Value to Invested Capital (EV/IC)	3.37	2.77	2.55
Enterprise Value to Revenue (EV/Rev)	1.95	1.61	1.33
Enterprise Value to EBITDA (EV/EBITDA)	10.88	8.12	6.59
Enterprise Value to EBIT (EV/EBIT)	29.27	20.43	15.17
Enterprise Value to NOPAT (EV/NOPAT)	47.37	28.89	23.58
Enterprise Value to Operating Cash Flow (EV/OCF)	9.75	6.52	7.62
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	140.85
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.06	0.03
Long-Term Debt to Equity	0.00	0.05	0.03
Financial Leverage	-0.21	-0.12	-0.10
Leverage Ratio	1.22	1.29	1.34
Compound Leverage Factor	1.19	1.29	1.11
Debt to Total Capital	0.00%	5.85%	2.91%
Short-Term Debt to Total Capital	0.00%	0.89%	0.30%
Long-Term Debt to Total Capital	0.00%	4.96%	2.61%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	1.39%
Common Equity to Total Capital	100.00%	94.15%	95.70%
Debt to EBITDA	0.00	0.19	0.09
Net Debt to EBITDA	0.00	-0.21	-0.36
Long-Term Debt to EBITDA	0.00	0.17	0.08
Debt to NOPAT	0.00	0.69	0.32
Net Debt to NOPAT	0.00	-0.73	-1.29
Long-Term Debt to NOPAT	0.00	0.59	0.28
Altman Z-Score	11.14	6.68	6.73
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.77%
Liquidity Ratios	-	-	-
Current Ratio	2.11	1.19	1.42
Quick Ratio	1.71	0.97	1.14
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-2.27	-16	2.11
Operating Cash Flow to CapEx	126.27%	192.19%	137.40%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	1.18	1.35	1.35
Accounts Receivable Turnover	9.85	10.82	10.34
Inventory Turnover	17.96	17.12	20.35
Fixed Asset Turnover	0.00	2.59	2.99
Accounts Payable Turnover	18.39	20.56	19.17
Days Sales Outstanding (DSO)	37.07	33.74	35.29
Days Inventory Outstanding (DIO)	20.33	21.32	17.93
Days Payable Outstanding (DPO)	19.85	17.75	19.04
Cash Conversion Cycle (CCC)	37.55	37.30	34.18
Capital & Investment Metrics	-	-	-
Invested Capital	80	106	117
Invested Capital Turnover	1.82	1.96	2.01
Increase / (Decrease) in Invested Capital	7.98	26	11
Enterprise Value (EV)	271	295	298
Market Capitalization	287	302	312
Book Value per Share	$2.55	$2.96	$3.37
Tangible Book Value per Share	$2.55	$2.17	$2.51
Total Capital	97	121	137
Total Debt	0.00	7.07	4.00
Total Long-Term Debt	0.00	6.00	3.59
Net Debt	-17	-7.45	-16
Capital Expenditures (CapEx)	22	24	28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	3.97	-5.52	-1.58
Debt-free Net Working Capital (DFNWC)	21	7.32	16
Net Working Capital (NWC)	21	6.24	16
Net Nonoperating Expense (NNE)	-0.51	-0.04	1.22
Net Nonoperating Obligations (NNO)	-17	-7.45	-16
Total Depreciation and Amortization (D&A)	16	22	26
Debt-free, Cash-free Net Working Capital to Revenue	2.86%	-3.02%	-0.70%
Debt-free Net Working Capital to Revenue	15.04%	4.00%	7.12%
Net Working Capital to Revenue	15.04%	3.41%	6.94%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.16	$0.27	$0.29
Adjusted Weighted Average Basic Shares Outstanding	38.66M	38.35M	38.75M
Adjusted Diluted Earnings per Share	$0.16	$0.25	$0.28
Adjusted Weighted Average Diluted Shares Outstanding	39.81M	40.38M	40.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	38.17M	38.76M	39.52M
Normalized Net Operating Profit after Tax (NOPAT)	5.95	11	13
Normalized NOPAT Margin	4.29%	5.82%	5.63%
Pre Tax Income Margin	6.48%	7.86%	7.21%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.32%
Augmented Payout Ratio	153.78%	0.00%	0.32%

This table displays calculated financial ratios and metrics derived from Viemed Healthcare's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	22.11%	17.35%	22.64%	30.02%	38.15%	35.28%	27.90%	26.91%	17.41%	19.62%
EBITDA Growth	-2.40%	1.57%	20.05%	71.08%	81.02%	41.42%	25.65%	15.45%	20.94%	32.92%
EBIT Growth	-47.72%	-24.24%	-10.36%	190.01%	178.31%	48.92%	10.67%	5.17%	39.02%	60.46%
NOPAT Growth	-37.64%	-36.26%	-7.98%	216.95%	182.38%	50.70%	14.57%	7.63%	37.99%	24.96%
Net Income Growth	-41.03%	-40.35%	-13.90%	140.95%	176.68%	42.62%	5.67%	-36.61%	33.78%	27.24%
EPS Growth	-25.00%	-30.00%	0.00%	200.00%	133.33%	14.29%	0.00%	-33.33%	42.86%	25.00%
Operating Cash Flow Growth	58.55%	-11.22%	46.88%	54.12%	73.22%	72.88%	-88.81%	33.57%	-7.71%	12.82%
Free Cash Flow Firm Growth	68.13%	44.68%	110.15%	-129.38%	-491.90%	-306.01%	-3,796.13%	77.18%	85.12%	73.56%
Invested Capital Growth	9.05%	11.06%	0.46%	43.89%	44.91%	32.76%	59.38%	8.67%	7.89%	9.88%
Revenue Q/Q Growth	7.35%	4.89%	5.46%	9.49%	14.06%	2.71%	-0.29%	8.64%	5.53%	4.64%
EBITDA Q/Q Growth	19.14%	40.02%	-14.29%	19.65%	26.06%	9.39%	-23.85%	9.95%	32.04%	20.23%
EBIT Q/Q Growth	52.45%	131.59%	-42.98%	44.07%	46.30%	23.92%	-57.63%	36.91%	93.38%	43.04%
NOPAT Q/Q Growth	47.07%	134.38%	-39.52%	52.04%	31.03%	25.09%	-54.02%	42.82%	68.00%	13.27%
Net Income Q/Q Growth	9.10%	131.09%	-37.78%	53.59%	25.28%	19.12%	-53.90%	-7.86%	164.39%	13.29%
EPS Q/Q Growth	50.00%	133.33%	-42.86%	50.00%	16.67%	14.29%	-50.00%	0.00%	150.00%	0.00%
Operating Cash Flow Q/Q Growth	61.18%	-3.61%	36.60%	-27.37%	81.15%	-3.80%	-91.15%	766.55%	25.17%	17.59%
Free Cash Flow Firm Q/Q Growth	61.78%	-7.26%	120.06%	-2,889.52%	1.38%	26.42%	-69.99%	82.78%	35.71%	-30.76%
Invested Capital Q/Q Growth	-1.52%	6.92%	-9.65%	51.24%	-0.82%	-2.04%	6.78%	3.12%	-1.53%	-0.24%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	60.55%	61.04%	60.68%	60.28%	61.86%	63.29%	58.91%	59.84%	59.26%	59.54%
EBITDA Margin	15.79%	21.08%	17.13%	18.72%	20.69%	22.04%	16.83%	17.03%	21.31%	24.49%
Operating Margin	4.11%	9.42%	4.89%	6.70%	8.51%	10.42%	4.36%	6.58%	9.70%	10.63%
EBIT Margin	4.27%	9.42%	5.09%	6.70%	8.60%	10.37%	4.41%	5.55%	10.18%	13.91%
Profit (Net Income) Margin	2.95%	6.50%	3.84%	5.38%	5.91%	6.85%	3.17%	2.69%	6.73%	7.29%
Tax Burden Percent	69.82%	68.02%	75.17%	76.19%	68.86%	68.50%	75.58%	65.79%	71.01%	70.17%
Interest Burden Percent	99.02%	101.41%	100.15%	105.34%	99.81%	96.45%	95.11%	73.53%	93.14%	74.66%
Effective Tax Rate	30.18%	31.98%	24.83%	23.81%	31.14%	31.50%	24.42%	34.21%	28.99%	29.83%
Return on Invested Capital (ROIC)	5.32%	11.68%	7.43%	8.58%	10.84%	14.00%	6.80%	7.79%	13.07%	14.97%
ROIC Less NNEP Spread (ROIC-NNEP)	5.17%	11.51%	7.19%	6.59%	10.60%	15.20%	7.24%	-53.47%	14.96%	15.84%
Return on Net Nonoperating Assets (RNNOA)	-1.12%	-2.37%	-1.89%	-0.40%	-1.00%	-1.76%	-0.95%	-0.70%	-0.62%	-1.52%
Return on Equity (ROE)	4.20%	9.31%	5.54%	8.18%	9.84%	12.25%	5.85%	7.09%	12.46%	13.45%
Cash Return on Invested Capital (CROIC)	1.16%	-2.98%	7.26%	-28.35%	-26.90%	-17.22%	-34.71%	0.97%	2.78%	1.89%
Operating Return on Assets (OROA)	4.84%	11.13%	6.11%	7.90%	10.86%	13.96%	6.12%	7.30%	13.68%	18.80%
Return on Assets (ROA)	3.35%	7.68%	4.60%	6.34%	7.46%	9.22%	4.40%	3.53%	9.05%	9.85%
Return on Common Equity (ROCE)	4.20%	9.31%	5.54%	8.18%	9.84%	12.25%	5.85%	7.03%	12.36%	13.35%
Return on Equity Simple (ROE_SIMPLE)	8.38%	0.00%	5.97%	7.02%	8.46%	0.00%	8.88%	7.94%	8.37%	0.00%
Net Operating Profit after Tax (NOPAT)	1.03	2.40	1.45	2.21	2.90	3.62	1.67	2.38	4.00	4.53
NOPAT Margin	2.87%	6.41%	3.68%	5.10%	5.86%	7.14%	3.29%	4.33%	6.89%	7.46%
Net Nonoperating Expense Percent (NNEP)	0.15%	0.17%	0.25%	1.99%	0.24%	-1.20%	-0.44%	61.26%	-1.89%	-0.87%
Return On Investment Capital (ROIC_SIMPLE)	-	2.48%	-	-	-	2.99%	-	-	-	3.30%
Cost of Revenue to Revenue	39.45%	38.96%	39.32%	39.72%	38.14%	36.71%	41.09%	40.16%	40.74%	40.46%
SG&A Expenses to Revenue	49.43%	45.78%	49.96%	47.48%	47.88%	47.11%	49.05%	48.22%	45.98%	46.48%
R&D to Revenue	1.87%	1.92%	1.97%	1.75%	1.20%	1.28%	1.48%	1.38%	1.31%	1.32%
Operating Expenses to Revenue	56.60%	54.11%	56.00%	53.58%	53.43%	52.81%	54.60%	52.24%	50.03%	52.19%
Earnings before Interest and Taxes (EBIT)	1.53	3.53	2.02	2.90	4.25	5.26	2.23	3.05	5.90	8.45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	5.65	7.91	6.78	8.11	10	11	8.52	9.36	12	15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.44	2.96	3.69	3.58	2.38	2.65	3.14	2.13	2.28	2.38
Price to Tangible Book Value (P/TBV)	2.44	2.96	3.69	5.05	3.30	3.62	4.25	2.98	3.12	3.20
Price to Revenue (P/Rev)	1.72	2.07	2.52	2.40	1.52	1.65	1.88	1.24	1.33	1.39
Price to Earnings (P/E)	28.71	46.20	58.95	49.14	27.58	29.50	35.38	26.86	27.30	27.72
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.48%	2.16%	1.70%	2.04%	3.63%	3.39%	2.83%	3.72%	3.66%	3.61%
Enterprise Value to Invested Capital (EV/IC)	2.80	3.37	4.74	3.46	2.38	2.77	3.16	2.14	2.37	2.55
Enterprise Value to Revenue (EV/Rev)	1.58	1.95	2.35	2.43	1.52	1.61	1.88	1.24	1.30	1.33
Enterprise Value to EBITDA (EV/EBITDA)	8.84	10.88	13.76	13.41	7.85	8.12	9.59	6.49	6.71	6.59
Enterprise Value to EBIT (EV/EBIT)	22.38	29.27	43.23	38.57	20.54	20.43	24.90	17.24	16.88	15.17
Enterprise Value to NOPAT (EV/NOPAT)	29.74	47.37	61.49	53.44	28.79	28.89	35.05	24.04	23.70	23.58
Enterprise Value to Operating Cash Flow (EV/OCF)	7.31	9.75	11.04	11.23	6.52	6.52	10.16	6.63	7.43	7.62
Enterprise Value to Free Cash Flow (EV/FCFF)	251.78	0.00	65.42	0.00	0.00	0.00	0.00	230.58	88.35	140.85
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.05	0.00	0.00	0.15	0.09	0.06	0.06	0.08	0.04	0.03
Long-Term Debt to Equity	0.04	0.00	0.00	0.12	0.07	0.05	0.05	0.07	0.03	0.03
Financial Leverage	-0.22	-0.21	-0.26	-0.06	-0.09	-0.12	-0.13	0.01	-0.04	-0.10
Leverage Ratio	1.28	1.22	1.24	1.34	1.33	1.29	1.29	1.39	1.35	1.34
Compound Leverage Factor	1.27	1.24	1.24	1.41	1.32	1.24	1.23	1.02	1.26	1.00
Debt to Total Capital	4.40%	0.00%	0.00%	12.76%	8.36%	5.85%	5.30%	7.26%	3.40%	2.91%
Short-Term Debt to Total Capital	0.17%	0.00%	0.00%	2.65%	1.54%	0.89%	0.49%	0.59%	0.62%	0.30%
Long-Term Debt to Total Capital	4.23%	0.00%	0.00%	10.11%	6.82%	4.96%	4.81%	6.67%	2.78%	2.61%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.38%	1.40%	1.39%
Common Equity to Total Capital	95.60%	100.00%	100.00%	87.24%	91.64%	94.15%	94.70%	91.36%	95.20%	95.70%
Debt to EBITDA	0.18	0.00	0.00	0.54	0.30	0.19	0.17	0.24	0.11	0.09
Net Debt to EBITDA	-0.82	0.00	0.00	0.18	0.00	-0.21	-0.02	-0.03	-0.21	-0.36
Long-Term Debt to EBITDA	0.17	0.00	0.00	0.43	0.25	0.17	0.16	0.22	0.09	0.08
Debt to NOPAT	0.61	0.00	0.00	2.15	1.11	0.69	0.62	0.89	0.38	0.32
Net Debt to NOPAT	-2.74	0.00	0.00	0.71	-0.02	-0.73	-0.08	-0.11	-0.74	-1.29
Long-Term Debt to NOPAT	0.59	0.00	0.00	1.71	0.90	0.59	0.57	0.82	0.31	0.28
Altman Z-Score	7.58	10.98	11.24	6.87	5.80	6.48	7.77	5.68	6.16	6.52
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.80%	0.78%	0.77%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.09	2.11	1.99	1.14	1.14	1.19	1.28	1.43	1.31	1.42
Quick Ratio	1.88	1.71	1.79	0.89	0.89	0.97	1.06	1.20	1.10	1.14
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-5.20	-5.58	1.12	-31	-31	-23	-41	-7.12	-4.58	-5.99
Operating Cash Flow to CapEx	130.62%	142.88%	268.78%	149.88%	195.90%	177.47%	21.90%	124.66%	256.49%	150.65%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.13	1.18	1.20	1.18	1.26	1.35	1.39	1.31	1.34	1.35
Accounts Receivable Turnover	9.63	9.85	9.77	9.70	10.32	10.82	9.51	9.15	9.53	10.34
Inventory Turnover	17.88	17.96	19.22	16.78	16.87	17.12	19.36	18.05	18.96	20.35
Fixed Asset Turnover	2.10	0.00	2.21	0.00	2.40	2.59	2.73	2.79	2.90	2.99
Accounts Payable Turnover	12.24	18.39	14.37	12.46	13.63	20.56	15.00	12.85	14.21	19.17
Days Sales Outstanding (DSO)	37.90	37.07	37.36	37.61	35.37	33.74	38.37	39.89	38.30	35.29
Days Inventory Outstanding (DIO)	20.42	20.33	18.99	21.76	21.63	21.32	18.85	20.22	19.25	17.93
Days Payable Outstanding (DPO)	29.82	19.85	25.40	29.30	26.78	17.75	24.33	28.40	25.69	19.04
Cash Conversion Cycle (CCC)	28.49	37.55	30.95	30.07	30.23	37.30	32.89	31.71	31.86	34.18
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	75	80	72	110	109	106	115	119	117	117
Invested Capital Turnover	1.85	1.82	2.02	1.68	1.85	1.96	2.07	1.80	1.90	2.01
Increase / (Decrease) in Invested Capital	6.23	7.98	0.34	33	34	26	43	9.50	8.58	11
Enterprise Value (EV)	210	271	343	379	258	295	365	255	278	298
Market Capitalization	229	287	369	374	258	302	365	254	285	312
Book Value per Share	$2.46	$2.55	$2.62	$2.73	$2.83	$2.96	$3.00	$3.07	$3.22	$3.37
Tangible Book Value per Share	$2.46	$2.55	$2.62	$1.93	$2.04	$2.17	$2.22	$2.20	$2.35	$2.51
Total Capital	98	97	100	120	119	121	123	131	131	137
Total Debt	4.32	0.00	0.00	15	9.93	7.07	6.50	9.49	4.46	4.00
Total Long-Term Debt	4.16	0.00	0.00	12	8.10	6.00	5.91	8.72	3.65	3.59
Net Debt	-19	-17	-26	5.06	-0.15	-7.45	-0.81	-1.11	-8.68	-16
Capital Expenditures (CapEx)	6.10	5.38	3.91	5.09	7.05	7.49	5.37	8.17	4.97	9.95
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1.23	3.97	-2.25	-2.68	-3.94	-5.52	1.79	3.67	-1.08	-1.58
Debt-free Net Working Capital (DFNWC)	22	21	23	7.54	6.14	7.32	9.10	14	12	16
Net Working Capital (NWC)	22	21	23	4.37	4.31	6.24	8.50	13	11	16
Net Nonoperating Expense (NNE)	-0.03	-0.03	-0.06	-0.12	-0.02	0.15	0.06	0.90	0.09	0.10
Net Nonoperating Obligations (NNO)	-19	-17	-28	5.06	-0.15	-7.45	-0.81	-2.11	-9.55	-16
Total Depreciation and Amortization (D&A)	4.12	4.37	4.76	5.21	5.98	5.92	6.29	6.31	6.46	6.42
Debt-free, Cash-free Net Working Capital to Revenue	-0.92%	2.86%	-1.54%	-1.72%	-2.32%	-3.02%	0.92%	1.78%	-0.50%	-0.70%
Debt-free Net Working Capital to Revenue	16.86%	15.04%	15.93%	4.83%	3.62%	4.00%	4.69%	6.94%	5.63%	7.12%
Net Working Capital to Revenue	16.74%	15.04%	15.93%	2.80%	2.54%	3.41%	4.38%	6.56%	5.25%	6.94%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.03	$0.07	$0.04	$0.06	$0.08	$0.09	$0.04	$0.04	$0.10	$0.11
Adjusted Weighted Average Basic Shares Outstanding	38.23M	38.66M	38.16M	38.32M	38.44M	38.35M	38.72M	38.82M	38.87M	38.75M
Adjusted Diluted Earnings per Share	$0.03	$0.07	$0.04	$0.06	$0.07	$0.08	$0.04	$0.04	$0.10	$0.10
Adjusted Weighted Average Diluted Shares Outstanding	39.58M	39.81M	40.02M	40.68M	40.42M	40.38M	40.58M	40.55M	40.78M	40.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	38.02M	38.17M	38.28M	38.40M	38.49M	38.76M	38.82M	38.83M	38.94M	39.52M
Normalized Net Operating Profit after Tax (NOPAT)	1.23	2.53	1.44	2.30	3.09	3.81	1.83	2.02	3.66	4.53
Normalized NOPAT Margin	3.44%	6.73%	3.63%	5.31%	6.25%	7.51%	3.61%	3.68%	6.32%	7.46%
Pre Tax Income Margin	4.23%	9.56%	5.10%	7.06%	8.58%	10.00%	4.19%	4.08%	9.48%	10.39%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.32%
Augmented Payout Ratio	112.54%	153.78%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.32%

Financials Breakdown Chart

Key Financial Trends

Here is a concise, data-driven snapshot of Viemed Healthcare (VMD) using the last four years of quarterly results in the provided data. The focus is on trends in revenue, margins, cash flow, and balance sheet strength to help you gauge the stock’s profitability and liquidity trajectory.

Revenue growth trend: Operating revenue rose from about $37.5 million in 2022 Q3 to about $60.7 million in 2024 Q4, reflecting continued top‑line expansion over the period.
Stable gross margins: Total gross margin held around 60%–63% across the visits, indicating stable pricing/mix even as volumes grew.
Improving operating profitability: Operating income margin expanded in 2024 to roughly the 10%–11% range, signaling better control of operating costs relative to revenue.
Solid net income progression: Net income attributable to common shareholders reached about $4.32 million in 2024 Q4, with a net margin near 7%, suggesting improving bottom-line performance as the business scales.
Healthy operating cash flow: Cash from continuing operating activities remained robust and positive, with 2024 Q4 net cash from continuing operations around $14.99 million, underscoring strong liquidity from core operations.
Strengthening equity base: Total equity (including noncontrolling interests) rose over time, with the balance sheet showing a solid equity cushion (~$124.96 million equity by 2024 Q3 data), supporting financial flexibility.
Modest leverage: Debt levels are relatively low (short-term debt around $0.8 million and long-term debt around $3.65 million in recent periods), indicating a modest leverage profile for a growth-focused healthcare company.

Growth investments in SG&A and R&D: Selling, General & Administrative expenses and R&D expenses are ongoing and substantial components of the cost structure. While they support growth, they remain a meaningful use of dollars relative to revenue, which is a neutral factor for the near-term margin trajectory.
Intangible assets and goodwill trend: Goodwill and intangible assets have grown across the period (e.g., goodwill around $32.99 million and related intangibles on the balance sheet), suggesting past acquisitions or capitalization activity. This is neutral for near-term earnings but could affect future impairment risk if growth decelerates.
Liquidity context: Cash balances are solid but modest (cash and equivalents in the low-to-mid-teens of millions across recent quarters). Positive operating cash flow supports liquidity, but the overall cash position is not expansive relative to scale, which is a neutral framing for risk assessment.

Expense load relative to revenue: SG&A and related operating expenses remain a meaningful portion of revenue, which can cap further margin expansion if top-line growth slows.
Significant capex activity: Capital expenditures on property, plant & equipment have been sizable (often around $8–13 million per quarter), creating sizable investing outflows and weighing on free cash flow in the near term.
Fluctuating financing cash flows: Cash flows from financing activities show variability due to debt repayments and potential equity actions, which can impact liquidity if operating cash flow weakens or if growth requires more external funding.

05/15/26 04:36 AM ETAI Generated. May Contain Errors.

Viemed Healthcare Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Viemed Healthcare's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

Viemed Healthcare's net income appears to be on an upward trend, with a most recent value of $11.41 million in 2024, rising from $6.22 million in 2022. The previous period was $10.24 million in 2023. Find out what analysts predict for Viemed Healthcare in the coming months.

Viemed Healthcare's total operating income in 2024 was $17.90 million, based on the following breakdown:

Total Gross Profit: $133.20 million
Total Operating Expenses: $117.04 million

Over the last 2 years, Viemed Healthcare's total revenue changed from $138.83 million in 2022 to $224.26 million in 2024, a change of 61.5%.

Viemed Healthcare's total liabilities were at $43.77 million at the end of 2024, a 6.8% increase from 2023, and a 119.4% increase since 2022.

In the past 2 years, Viemed Healthcare's cash and equivalents has ranged from $12.84 million in 2023 to $17.54 million in 2024, and is currently $17.54 million as of their latest financial filing in 2024.

Over the last 2 years, Viemed Healthcare's book value per share changed from 2.55 in 2022 to 3.37 in 2024, a change of 32.1%.

Related Companies

Financial statements for NASDAQ:VMD last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viemed Healthcare (VMD) Financials

Financials Breakdown Chart

Key Financial Trends

Viemed Healthcare Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viemed Healthcare (VMD) Financials

Annual Income Statements for Viemed Healthcare

Quarterly Income Statements for Viemed Healthcare

Annual Cash Flow Statements for Viemed Healthcare

Quarterly Cash Flow Statements for Viemed Healthcare

Annual Balance Sheets for Viemed Healthcare

Quarterly Balance Sheets for Viemed Healthcare

Annual Metrics And Ratios for Viemed Healthcare

Quarterly Metrics And Ratios for Viemed Healthcare

Financials Breakdown Chart

Key Financial Trends

Viemed Healthcare Financials - Frequently Asked Questions

When does Viemed Healthcare's financial year end?

How has Viemed Healthcare's net income changed over the last 2 years?

What is Viemed Healthcare's operating income?

How has Viemed Healthcare's revenue changed over the last 2 years?

How much debt does Viemed Healthcare have?

How much cash does Viemed Healthcare have?

How has Viemed Healthcare's book value per share changed over the last 2 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools